One dose of psilocybin, the active ingredient in the psychedelic class A drug “magic mushrooms”, has a sustained and significant effect in treating cases of depression that are unresponsive to other drugs, a study has found.
A peer-reviewed, mid-stage trial published in the New England Journal of Medicine on Wednesday found one 25mg dose of the drug, alongside psychotherapeutic support, “significant[ly]” reduced symptoms of depression in patients who did not respond to other medication.
Researchers said the study, led by UK-based pharmaceutical group Compass Pathways, was the largest to date on the use of psilocybin as a treatment for depression and that its findings paved the way for regulatory approval.
您已阅读20%（712字），剩余80%（2866字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。